TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07681596: A Modular, Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Efficacy of AZD4045, an Allogeneic Chimeric Antigen Receptor-T Cell (CAR-T) Therapy Targeting B Cell Matur

Sponsor: AstraZeneca · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 101 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$8,875,020

Rescue Site Savings

+$5,851,230

Unlock Full NCT07681596 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07681596 Rescue Dossier →